Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Vident Advisory LLC

Vident Advisory LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1,269.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 99,348 shares of the life sciences company’s stock after acquiring an additional 92,092 shares during the quarter. Vident Advisory LLC owned about 0.06% of Illumina worth $13,276,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Capital World Investors boosted its position in Illumina by 408.6% in the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock valued at $2,408,721,000 after buying an additional 14,481,232 shares during the last quarter. Brown Advisory Inc. grew its position in Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock worth $255,586,000 after purchasing an additional 1,909,118 shares during the period. Norges Bank purchased a new position in shares of Illumina during the 4th quarter valued at about $228,714,000. Bessemer Group Inc. lifted its holdings in shares of Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock valued at $180,152,000 after buying an additional 1,344,038 shares during the period. Finally, WCM Investment Management LLC boosted its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after buying an additional 867,673 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the company’s stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Stephens reiterated an “overweight” rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Robert W. Baird cut their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Piper Sandler decreased their target price on Illumina from $190.00 to $185.00 and set an “overweight” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. dropped their target price on shares of Illumina from $120.00 to $85.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Finally, Royal Bank of Canada dropped their price target on Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.70.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $83.62 on Monday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm has a market capitalization of $13.24 billion, a P/E ratio of -10.89, a P/E/G ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company’s fifty day moving average price is $78.48 and its 200 day moving average price is $110.89.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.98 earnings per share. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.